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COMMENTARY
A one stop shop for cost-efectiveness 
evidence? Recommendations for improving 
Disease Control Priorities
Matthias Arnold*, Susan Griffin, Jessica Ochalek, Paul Revill and Simon Walker
Abstract 
Setting out a health benefits package (HBP) of interventions to be prioritised for funding is an important step towards 
achieving universal health coverage in low and middle income countries. The 3rd version of the Disease Control Priori-
ties (DCP3) database, and other similar databases, aim to establishing a single point of reference (“one stop shop”) 
for cost effectiveness evidence to inform HBP design and other policy making. We reflect upon our experiences in 
using DCP3 for HBP design and offer suggestions for improving the future reporting of cost-effectiveness evidence. 
We appraise DCP3 based on generalisability, level of detail, and accessibility. We find that DCP and similar initiatives 
should be commended for the systematic assessment of a vast array of cost-effectiveness studies—the magnitude of 
such an endeavour is impressive in its own right. However, there are flaws. In future, providing disaggregated esti-
mates of costs and effects, quantifying uncertainty, and systematically assessing the context in which estimates apply 
would make this evidence more useful for decision makers.
© The Author(s) 2019. This article is distributed under the terms of the Creative Commons Attribution 4.0 International License 
(http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, 
provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, 
and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/
publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Setting out a health beneits package (HBP) of interven-
tions to be prioritised for funding is an important step 
towards achieving universal health coverage. Low and 
middle-income countries (LMIC) experience severe 
constraints on funding, posing serious challenges for 
resource allocation. here is growing awareness that 
HBPs are an important tool for guiding policies aimed 
towards the goal of universal access. HBP design was 
noted as a priority topic in the Health Ministers’ Con-
ference of the East, Central, and Southern Africa Health 
Community [1]. here are recent examples of HBPs 
being designed and implemented in African [2] and Latin 
American [3] countries.
hree notable databases aim at providing single points 
of reference (“one stop shops”) for cost-efectiveness evi-
dence to inform HBP design: the World Health Organi-
zation Cost-Efectiveness program (WHO-CHOICE), 
the Global Health Cost-Efectiveness Analysis Registry 
by the Tufts Medical Center, and the Disease Control 
Priorities (DCP) project with its newest version DCP3. 
DCP3 has received particular attention due to major 
investment by the Bill & Melinda Gates Foundation and a 
publication series in the Lancet [4]. Here we relect upon 
our experiences in using DCP evidence for HBP design. 
We highlight problems that analysts may encounter in 
using DCP3 as a single point of reference from which to 
extract cost-efectiveness evidence. We ofer suggestions 
for improved reporting of intervention cost-efectiveness 
studies in future iterations of DCP and other similar 
initiatives.
Costs and efects, more than just ratios
he results of published cost-efectiveness studies in 
DCP3 are typically summarised as the ratio of the incre-
mental cost and beneit between an intervention and a 
relevant comparator (i.e., incremental cost-efectiveness 
ratio, ICER). More often than not, the comparator against 
which the ICER is calculated is not reported in DCP3. 
his makes it challenging to use this data and assess what 
estimates really mean in any particular context in which 
they are applied. In judging the gain from including an 
intervention in a HBP it is the increment compared to the 
appropriate comparator that is of interest. Appropriate 
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comparators, such as the available relevant alterna-
tive interventions and the standard of care, may difer 
between countries. herefore, we recommend reporting 
the comparator when ICERs or incremental costs and 
beneits are reported.
Ratios can be compared against a decision threshold 
or estimate of the marginal productivity of healthcare 
resources to inform decisions about cost-efectiveness. 
hey do not tell us anything about total health beneit or 
total costs associated with including an intervention in a 
HBP. In DCP3 efort was made to ill this gap by providing 
intervention costs in appendices, but these are available 
for only a fraction of interventions and are unfortunately 
not disaggregated in full by country or setting. Quan-
tifying the scale of the health beneits and cost of each 
intervention requires information about per patient cost 
and beneits alongside local data on the size of the patient 
population that stands to receive the intervention [5]. We 
recommend as a minimum the reporting of per patient 
incremental costs and beneits in these databases. For 
some situations, the marginal costs and beneits depend 
on the scale of delivery. In which case, additional infor-
mation on the scale of implementation and size of the eli-
gible patient population in the underlying studies would 
be useful in determining their relevance.
Comparing apples with apples, and discarding 
rotten apples
When using the results of previously published studies, 
analysts make judgements about their validity, generalis-
ability and uncertainty. his is crucial to determine the 
potential for bias and in understanding the conidence 
that can be placed in results and when extrapolating esti-
mates from one setting to another. In designing a HBP, 
estimates are required across a wide range of interven-
tions, and it is important to know how far the evidence 
for each is comparable. hese issues are particularly rel-
evant in drawing results from DCP3, which represents a 
compendium of global evidence.
DCP3 addresses the issue of validity by utilising a 
checklist for appraising study quality [6], which combines 
criteria for best practices in study design, methodology 
and reporting standards. Quality is presented as a sum 
score. While this allows for the identiication of stud-
ies with high scores, there is discussion in the literature 
about the appropriate of using checklist scores as a meas-
ure of quality and further it does not elaborate on the 
nature of any diferences between studies [7].
Beyond the scientiic rigour addressed in the check-
list, methodological choices also inluence cost efective-
ness results. For example, diferent choices relating to 
outcome measures, the time horizon, discounting and 
perspective can have substantial impact on the cost and 
efect estimates. Regarding outcomes, the two metrics 
used most often to inform resource allocation decisions 
across diferent diseases are the quality adjusted life year 
(QALY) and disability-adjusted life year (DALY). Both 
attempt to do similar things—they both are composite 
measures relecting mortality and morbidity. However, 
the diferences between them have been debated and 
database users may not want to treat them as exchange-
able. DCP3 report cost per DALY averted or QALY 
gained depending upon the outcome measure used in the 
underlying study, which is DALYs in most instances. DCP 
can only report what is available, but it should be explicit 
about which outcomes are included for each study.
Diferent cost estimates for the same intervention 
can also be produced by, for instance, using the top-
down (splitting up aggregate provider cost or insurance 
claims into distinct intervention shares) or bottom-up 
approaches (micro-costing all ingredients necessary). 
DCP3 addresses this by using the latter if available, but 
considerable variation nevertheless remains. Again, being 
explicit about the method by which the costs were pro-
duced allows users to consider themselves the extent to 
which studies are valid and comparable. Factors to report 
include the time horizon; the discount rates used for 
costs and beneits and the study perspective.
DCP3 report the country or region of origin of ratio 
estimates. To be useful across a wide range of countries, 
DCP3 relies heavily upon assumptions of generalizability. 
Determining whether cost-efectiveness evidence is gen-
eralizable requires assessment of (i) the similarity of the 
contexts and (ii) the sensitivity of the cost-efectiveness 
results to aspects that are dissimilar [8]. It is widely rec-
ognized that cost-efectiveness results can substantially 
difer across countries due to variation in (i) epidemiol-
ogy (e.g. disease prevalence and incidence, conditional 
survival); (ii) clinical efectiveness; and (iii) economic var-
iables, with both resource use and unit costs depending 
upon local factors. Reporting at a minimum per patient 
costs and health efects would allow potential users to 
assess whether such estimates conform to expectations 
given local epidemiological, administrative or expendi-
ture data. Reporting further details about the underlying 
study settings, such as the epidemiologic context, would 
better enable users to make assessments about generaliz-
ability. Even more valuable would be the reporting of sen-
sitivity analysis in the original studies that indicate how 
the costs and beneits difer with changes in particular 
parameters.
DCP3 does not systematically address uncertainty, 
but potential users can refer to the original studies in 
the appendices to make this assessment for themselves. 
Even if there is conidence in the validity (i.e. absence of 
bias) of results, there is inevitable uncertainty around any 
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estimates of cost-efectiveness. Uncertainty means that 
the results of subsequent analyses, for example the rec-
ommended HBP, may not provide best value. he true 
costs and health beneits can difer from the expected 
results. he likelihood of this informs the level of risk that 
service delivery cannot be maintained if the true costs 
exceed available resources, or that signiicant health ben-
eits are forgone [9]. Without information on the uncer-
tainty around estimates, it is not possible to assess the 
level of risk, to plan for the possibility of the budget being 
exceeded nor direct eforts to reducing the key sources 
of uncertainty. Presentation of point estimates only in the 
main text of DCP3 risks that users treat all results as if 
they are subject to the same degree of uncertainty. We 
recommend that DCP3 make clear where further infor-
mation on decision uncertainty is available in underlying 
studies (Boxes 1, 2).
1.00 implying neonatal death. With caesarean section, 
the mortality rate can be reduced to 11%.
his example demonstrates how important it is to 
check the appropriateness of a study when using it 
within a HBP design. Changes in maternal and neo-
natal mortality from obstructed labour and cae-
sarean sections have major implications for the 
calculation of DALYs averted. Without knowing the 
context from which estimates come and assumptions 
used in the calculation, transferring cost-efectiveness 
results risks misrepresenting local circumstances and 
misinforming decisions.
Box 1: Issues of generalisability—the example 
of emergency caesarean
his example illustrates generalisability issues by con-
trasting the information in the HBP in Malawi on the 
cost-efectiveness of emergency caesarean care, which 
is based on a study from a neighbouring country, with 
the information in DCP3 from a larger geographi-
cal context, to illustrate how such estimates might be 
used in HBP design.
In Malawi, the cost efectiveness of caesarean sec-
tion for obstructed labour is based on a study in Zam-
bia [10], which estimates that 27.19 DALY are averted 
at a cost of $300 in 2016 US$ per patient, resulting in 
an ICER of $11 per DALY averted. In DCP3, ICER 
estimates range from $1600 to $2600 in 2012 US$ per 
DALY averted for all LMIC [11]. Incremental averted 
DALYs and costs are not presented, and identify-
ing the source of this discrepancy requires reviewing 
the original study used in DCP3. he original study 
is an international modelling study over 49 countries 
reporting ICER ranges from $251 to $3462 with 45 of 
the 49 reporting ICERs below $1000 [12]. he model-
ling study estimates cost in Malawi to be at $133 and 
avert 0.48 DALY per caesarean, resulting in an ICER 
of $274 per DALY averted. Since these numbers are 
very diferent from the estimates from the study in 
Zambia, the methods and assumptions in both stud-
ies need to be compared. he main diference lies in 
the calculation of DALYs, which integrates averted 
disability and life lost in mothers and neonates in 
the Zambian study, but relects only the mother and 
not the neonate in the modelling study. he Zambian 
study assumes that neonatal disability weights, the 
proportion of quality of life lost due to disability, are at 
Box 2: Limits of cost‑efectiveness ratios—the example 
of insecticide treated nets for malaria prevention
his example illustrates the importance of reporting 
separately the cost and health impacts from imple-
menting interventions, and not just the ICERs.
DCP3 recommends supplying (insecticide treated 
nets) ITNs for malaria prevention (compared to stand-
ard of care, which is left unspeciied) at an ICER range 
of $61–94 [11]. Supplying households with ITNs and 
ensuring that pregnant women and children under-5 
all slept under ITNs were found to be cost-efective 
interventions for the Malawian EHP (with ICERs 
of $33, $34 and $35 per DALY averted respectively) 
[13]. To determine how much of the budget would 
be exhausted by the provision of these interventions, 
information on per patient cost was required in com-
bination with the data on the estimated populations 
in need in Malawi. his also enabled the calculation 
of the population health gains associated with that 
investment. To provide ITNs to all households requir-
ing them would cost $13.4 million and avert 228,000 
DALYs; ensuring pregnant women slept under an ITN 
would cost $3 million and avert 50,000 net DALYs; 
and ensuring children under-5 slept under an ITN 
would cost $1 million and avert 17,000 net DALYs.
However, in practice, as a result of health system 
constraints—including available clinic capacities, 
trained health care workers and accessibility to health 
care—it is estimated feasible attainable coverage lev-
els for supplying households with ITNs is only cur-
rently approximately 56%, (while, by comparison, full 
coverage is considered feasible for ensuring pregnant 
women and children under-5 sleep under an ITN 
given current constraints). he result is that 128,000 
net DALYs are averted out of the 228,000 that could be 
gained if this was provided at full coverage.
By using per patient incremental costs and 
health gains, it can be determined that an addition 
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population net health gain can be achieved of 79,000 
DALYs averted if the health system constraints can be 
overcome. his can also be used to inform the maxi-
mum that Malawi could spend to scale up the cover-
age of ITNs for households, $4.8 million, before it 
would be considered cost-inefective to do so.
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Accessibility and user‑friendliness of DCP3
DCP3 should be an easily accessible resource for a wide 
range of users. However, the presentation of DCP3 
results within chapters organized by disease area and 
without a combined database covering all interventions 
limits its user-friendliness. Selecting interventions to 
consider for inclusion in a HBP is fraught with di culty 
and the lists in DCP3 that rank interventions based on 
the ICER could be misleading for the reasons highlighted 
in this letter. We outline recommendations for improved 
reporting of cost-efectiveness studies in Box 3.
Box 3: Summary of recommendations
1. When reporting ICERs for an intervention, always 
specify the comparator.
2. Report per patient costs and per patient benefits, 
the country and setting to which they relate, and if 
possible the scale of delivery to which these relate.
3. Report benefits using generic measures of health, 
and distinguish between DALYs averted or QALYs 
gained.
4. Report methodological factors including the fol-
low-up/time horizon; the discount rate(s) used for 
costs and benefits, the study perspective.
5. Report context factors, including health system 
characteristics on a consistent basis.
6. Provide information on uncertainty.
Conclusion
DCP and similar initiatives should be commended for the 
systematic assessment of a vast array of cost-efectiveness 
studies—the magnitude of such an endeavour is impres-
sive in its own right. However, DCP3 alone does not 
provide “A concrete set of priorities for universal health 
coverage” that can reliably be taken up within any one 
country’s health care system. Its usefulness as a “one stop 
shop” to inform HBP design for moving toward univer-
sal health coverage would be greatly improved by imple-
menting some of the suggestions we have made here in 
the next iteration.
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